- 1、本文档共7页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
多吉美联合介入治疗原发性肝癌的疗效分析.
多吉美联合介入治疗原发性肝癌的疗效分析
(附20例病例报告)
作者:李枫,王峰,李军,杨新顺
单位:大连医科大学附属第一医院介入治疗科 辽宁大连 116001
第一作者:李枫,男,1973-05-16生,辽宁大连人,汉族,2003年获中国医科大学影像医学与核医学专业硕士学位,主治医师,主要从事肿瘤的介入治疗
E-mail:lifeng120@263.net
T通讯作者:王峰 大连医科大学附属第一医院介入治疗科 辽宁大连 116001
多吉美联合介入治疗原发性肝癌的疗效分析
(附20例病例报告)
李枫,王峰,李军,杨新顺
Efficacy analysis of Nexavar combined interventional therapy for hepatocellular carcinoma (study of 20 cases)
Feng Li, Feng Wang, Jun Li, Xin-Shun Yang
Feng Li, Feng Wang, Jun Li, Xin-Shun Yang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China
Correspondence to: Feng Wang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China.
Abstract
AIM: To study the efficacy comparison between Nexavar monotherapy and combined interventional therapy for treatment of hepatocellular carcinoma.
METHODS: Retrospective analysis of 20 cases who systemly taking Nexavar for hepatocellular carcinoma, including 7 cases of Nexavar monotherapy, 13 cases combined interventional therapy. All patients was followed up by hospital or out-patient for 7-28 months. Primary study endpoint was tumor response rate and time to tumor progression(TTP).
RESULTS: In 20 cases, 4 were achieved complete response (CR), 10 were partial response (PR), 4 with stable disease (SD) and 2 with progressed disease (PD). In Nexavar monotherapy group, CR was 0, PR was 3, SD was 2 and PD was 2. The median time to tumor progression was 16 weeks and 48 weeks respectively for Monotherapy group and combined treatment group.
CONCLUSION: Nexavar combined interventional therapy for hepatocellular carcinoma can increase the tumor response rate, extend the time to tumor progression.
Key words: Nexavar;interventional therapy;hepatocellular carcinoma;efficacy
摘要
目的:研究多吉美单药治疗肝癌与联合介入治疗的疗效对比。
方法:回顾性分析20例系统服用多吉美的肝癌患者,其中单药治疗的7例,联合介入治疗的13例,随访方式采用门诊随访及住院随访,随访时间7-28月。主要研究终点为肿瘤反应率和肿瘤进展时间。
结果:20例患者中,CR 4例,PR 10例,SD 4例,PD 2例,其中单药治疗组CR
文档评论(0)